Precision medicine

May 1, 2024

NCCN Recommends Universal Testing for Microsatellite Instability by PCR/NGS or Mismatch Repair by IHC for All Newly Diagnosed Gastric Cancer Patients

EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
October 19, 2023

It’s a MATCH: Peter O’Dwyer on the Future of Precision Oncology

Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
August 25, 2023

Amended Trial: Eligibility Expands in the EA8191/INDICATE Trial for Patients with Prostate Cancer

The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence